FMP
CymaBay Therapeutics Jumps 25% on Gilead Sciences’ $4.3 Billion Acquisition News
Feb 13, 2024 4:44 PM - Davit Kirakosyan
Image credit: FMP
Gilead Sciences (NASDAQ:GILD) revealed its plan to buy CymaBay Therapeutics (NASDAQ:CBAY) in a deal valued at $4.3 billion, aiming to enhance its liver disease treatment offerings. Following the announcement, CymaBay Therapeutics’ shares jumped more than 25% yesterday.
Gilead has agreed to purchase CymaBay at $32.50 per share in cash, with expectations to finalize the acquisition in the first quarter of 2024. This acquisition grants Gilead access to CymaBay's leading drug candidate, seladelpar, which is in development for treating primary biliary cholangitis, a chronic inflammatory condition of the liver.
Other Blogs
May 27, 2024 3:30 PM - Rajnish Katharotiya
The best 5 GPU stocks other than NVDA
In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...
Jun 6, 2024 2:47 AM - Parth Sanghvi
ROE vs ROA: Which Metric is More Important for Investors?
ROE vs. ROA: Which Metric is More Important for Investors? When evaluating a company's financial performance, investors often rely on various metrics to gauge profitability and efficiency. Two commonly discussed metrics are Return on Equity (ROE) and Return on Assets (ROA). Understanding the diff...
Jun 6, 2024 2:57 AM - Parth Sanghvi
DCF vs NPV: Which Valuation Method Should You Use?
When it comes to valuing an investment or a business, two of the most commonly used methods are Discounted Cash Flow (DCF) and Net Present Value (NPV). Both methods are essential tools in finance, but they serve slightly different purposes and are used in different contexts. This guide will explore ...
